[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 20, Issue 2 (summer 2021) ::
J Ardabil Univ Med Sci 2021, 20(2): 176-187 Back to browse issues page
Taking Renin-Angiotensin Drugs in Patients with COVID-19: Start, Continue, or Stop; a Literature Review
Mohammad Bagher Sharifkazemi
Department of Cardiovascular Diseases, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract:   (198 Views)
Considering the pandemic of the COVID-19 disease, the use of various drugs in patients has been investigated. Recently, numerous studies have been done on the effectiveness of drugs which used to treat the underlying disease such as congestive heart failure, hypertension, as well as coronary artery disease in various countries, because the patients with underlying conditions are more likely to develop COVID-19 disease.
Two classes of the most commonly used drugs in these underlying diseases are angiotensin converting enzyme inhibitor and angiotensin-receptor-blocking drugs. Because the two classes of drugs that mentioned above increase the levels of enzyme-converting enzyme receptor-2, it has been hypothesized that the initiation or continuation of such drugs will play some roles in initiation, progression or acceleration of the COVID-19 disease. In the case of a COVID-19 pandemic, there are some questions; which method should be chosen? start, continue or stop of the two classes of drugs as well as which one should be chosen to have a lower risk in patients suffering from COVID-19?. Accordingly, the studies reported from different countries which conducted with the aim of investigating this assumption, was reviewed in this article. As a result, all of those studies have announced this common result that the start-up order for these two groups of drugs in patients with COVID-19, who have underlying cardiovascular disease, should be treated in the same way as other patients, based on valid and accepted current guidelines. Furthermore, do not discontinue these medications if the patient has taken any of them before having COVID-19 disease.
Keywords: Renin-Angiotensin System, Covid-19, Cardiovascular Diseases
Full-Text [PDF 1101 kb]   (77 Downloads)    
Type of Study: review article | Subject: قلب و عروق
Received: 2020/07/27 | Accepted: 2021/01/29 | Published: 2021/01/29
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sharifkazemi M B. Taking Renin-Angiotensin Drugs in Patients with COVID-19: Start, Continue, or Stop; a Literature Review. J Ardabil Univ Med Sci. 2021; 20 (2) :176-187
URL: http://jarums.arums.ac.ir/article-1-1892-en.html

Volume 20, Issue 2 (summer 2021) Back to browse issues page
مجله دانشگاه علوم پزشکی اردبیل Journal of Ardabil University of Medical Sciences
Persian site map - English site map - Created in 0.08 seconds with 29 queries by YEKTAWEB 4284